###begin article-title 0
Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 283 286 283 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 301 304 301 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
The stroma is the supportive framework of biologic tissue in the breast, consisting of various proteins such as the proteoglycans, decorin and lumican. Altered expression of decorin and lumican is associated with breast tumors. We hypothesized that genetic variation in the decorin (DCN) and lumican (LUM) genes may contribute to breast cancer.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 132 136 <span type="species:ncbi:162683">Mayo</span>
###xml 223 227 <span type="species:ncbi:162683">Mayo</span>
We investigated associations of 14 common polymorphisms in the DCN and LUM genes with 798 breast cancer cases and 843 controls from Mayo Clinic, MN, USA. One polymorphism per gene with the strongest risk association in the Mayo Clinic sample was genotyped in 4,470 breast cancer cases and 4,560 controls from East Anglia, England (Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH)).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 87 93 87 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 125 129 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 363 364 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 364 369 362 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 502 503 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 503 508 501 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 661 662 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 662 667 660 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 901 902 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 902 907 900 905 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 1020 1021 1018 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1021 1026 1019 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 1142 1143 1140 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1143 1148 1141 1146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 7 11 <span type="species:ncbi:162683">Mayo</span>
###xml 401 405 <span type="species:ncbi:162683">Mayo</span>
###xml 801 805 <span type="species:ncbi:162683">Mayo</span>
In the Mayo Clinic sample, six polymorphisms were associated with breast cancer risk (Ptrend </= 0.05). The association with LUM rs2268578, evaluated further in SEARCH, was positive, although the odds ratios (OR) were weaker and not statistically significant. ORs were 1.4 (95% confidence interval [CI], 1.1 to 1.8) for heterozygotes and 2.2 (95% CI, 1.1 to 4.3; P2 df = 0.002) for homozygotes in the Mayo Clinic sample, and were 1.1 (95% CI, 0.9 to 1.2) for heterozygotes and 1.4 (95% CI, 1.0 to 2.1; P2 df = 0.13) for homozygotes in the SEARCH sample. In combined analyses, the ORs were 1.1 (95% CI, 1.0 to 1.2) for heterozygotes and 1.6 (95% CI, 1.2 to 2.3; P2 df = 0.005) for homozygotes. Positive associations for this polymorphism were observed for estrogen receptor-positive tumors in both the Mayo Clinic sample (OR for heterozygotes = 1.5, 1.1 to 1.9 and OR for homozygotes = 2.5, 1.2 to 5.3;P2 df = 0.001) and the SEARCH sample (OR for heterozygotes = 1.0, 0.9 to 1.1 and OR for homozygotes = 1.6, 1.0 to 2.5; P2 df = 0.10). In combined analyses, the ORs were 1.1 (95% CI, 0.9 to 1.2) for heterozygotes and 1.9 (95% CI, 1.3 to 2.8; P2 df = 0.001) for homozygotes.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 64 68 <span type="species:ncbi:162683">Mayo</span>
Although LUM rs2268578 was associated with breast cancer in the Mayo Clinic study, particularly estrogen receptor-positive breast cancer, weaker and modest associations were observed in the SEARCH sample. These modest associations will require larger samples to adequately assess the importance of this polymorphism in breast cancer.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 56 57 56 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Stromal changes are well documented in breast tumors [1,2] and in preinvasive breast lesions [2,3], and are hypothesized to play a role in breast cancer. The stroma may lead to morphologic changes that manifest as tumors through a stromal reaction or perturbation of epithelium [4] or, conversely, may play an initial landscaping role in tumorigenesis independent of epithelial neoplastic alterations [5].
###end p 11
###begin p 12
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 483 486 483 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 509 512 509 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 884 885 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 444 448 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The stroma is the supportive framework of biologic tissue consisting of an extensive extracellular matrix that supports cells, separates tissues and regulates intercellular communication. The extracellular matrix is composed of different proteins: decorin and lumican are members of the small leucine-rich proteoglycan family of proteins and are involved in matrix assembly and structure, and in the control of cell proliferation [6]. Knockout mice deficient for either the decorin (DCN) gene or the lumican (LUM) gene are viable, but show skin fragility, marked reductions in tensile strength and loosely packed collagen fibers with abnormal sheath diameters [7,8] - implicating the small leucine-rich proteoglycans as major regulators of collagen fibril assembly that probably play a role in the development of a barrier against cell penetration and infiltration of macromolecules [6].
###end p 12
###begin p 13
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Recent evidence supports an anti-oncogenic role for decorin. Injection of decorin protein into mammary carcinoma rodent models resulted in a marked reduction in both primary tumor growth and metastatic spread compared with animals injected with vehicle alone [9]. Low levels of decorin protein in invasive breast cancers have also been associated with larger tumor size, shortened duration to progression and poor outcome [10]. The role of lumican in carcinogenesis has been less well studied. Immunohistochemical analyses of breast tissue detected significantly higher lumican protein expression in tumors than in adjacent normal tissue, yet significantly lower decorin protein expression in tumors than in normal breast tissue [11]. Positive associations between decorin and lumican protein expression and mammographic density, a major risk factor for breast cancer, have also been observed [12]. These findings suggest that expression and/or activity of members of the small leucine-rich proteoglycan family may affect breast cancer risk.
###end p 13
###begin p 14
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 49 50 49 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 225 233 225 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori</italic>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
Given the role of the stroma in breast cancer [1,2], the occurrence of genetic alterations in the stroma of breast tumors [13-15] and the putative contribution of decorin and lumican to this disease [10,11], we hypothesized, a priori, that common genetic variation in the DCN and LUM genes is associated with breast cancer risk. We evaluated this hypothesis using data from a clinic-based case-control study of breast cancer, with follow-up in a large British case-control study.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 4 <span type="species:ncbi:162683">Mayo</span>
Mayo Clinic study design and population
###end title 16
###begin p 17
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 4 8 <span type="species:ncbi:162683">Mayo</span>
###xml 149 153 <span type="species:ncbi:162683">Mayo</span>
###xml 286 290 <span type="species:ncbi:162683">Mayo</span>
The Mayo Clinic Breast Cancer study is an Institutional Review Board-approved, ongoing clinic-based case-control study initiated in February 2001 at Mayo Clinic, Rochester, MN, USA. The study design has been presented previously [16,17]. Clinic attendance formed the sampling frame for Mayo Clinic cases and controls.
###end p 17
###begin p 18
###xml 23 28 <span type="species:ncbi:9606">women</span>
###xml 179 184 <span type="species:ncbi:9606">Women</span>
###xml 312 316 <span type="species:ncbi:162683">Mayo</span>
###xml 433 437 <span type="species:ncbi:162683">Mayo</span>
Consecutive cases were women aged 18 years or older with histologically confirmed primary invasive breast carcinoma who were recruited within 6 months of their date of diagnosis. Women with a history of cancer (excluding nonmelanoma skin cancer) were ineligible. Cases lived in the six-state region that defines Mayo Clinic's primary service population (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota). Although Mayo Clinic is widely perceived to be a specialty tertiary care facility, it also provides primary care for over 500,000 individuals per year.
###end p 18
###begin p 19
###xml 328 332 <span type="species:ncbi:162683">Mayo</span>
Control individuals without prior history of cancer (other than nonmelanoma skin cancer) were frequency matched on age (5-year age category), race and six-state region of residence to cases. Controls were recruited from the outpatient practice of the Divisions of General Internal Medicine and Primary Care Internal Medicine at Mayo Clinic, where they were seen for routine medical examinations.
###end p 19
###begin p 20
###xml 47 59 <span type="species:ncbi:9606">participants</span>
###xml 169 174 <span type="species:ncbi:9606">women</span>
###xml 189 201 <span type="species:ncbi:9606">participants</span>
Written informed consent was obtained from all participants. Case participation was 69% and control participation was 71%. The present investigation genotyped Caucasian women (99% of study participants) enrolled up to 30 June 2005, representing 798 cases and 843 controls.
###end p 20
###begin p 21
Both the cases and controls completed a self-administered questionnaire comprised of known or suspected breast cancer risk factors, and they provided blood samples from which genomic DNA was isolated using the Gentra AutoPure LS Purgene salting out methodology (Gentra, Minneapolis, MN, USA). Quantities of 250 etag genomic DNA were adjusted to 50 etag/mul before genotyping and were verified using the PicoGreen dsDNA quantitation kit (Molecular Probes, Inc., Eugene, OR, USA). The samples were bar coded to ensure accurate and reliable sample processing and storage.
###end p 21
###begin title 22
SNP selection, genotyping and quality control
###end title 22
###begin p 23
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 322 323 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 323 325 321 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 861 865 846 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 913 917 898 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 987 991 <span type="species:ncbi:162683">Mayo</span>
All SNPs in the DCN and LUM genes within 5 kb of the largest cDNA isoform (genome build 35) were selected from the Caucasian samples within the HapMap Consortium's release 21 [18]. We applied the ldSelect program [19] to bin SNPs with minor allele frequency (MAF) >/= 0.05 and pairwise linkage disequilibrium threshold of r2 >/= 0.80. tagSNPs were selected from these bins that met the criteria for predicted likelihood of successful genotyping using the Illumina GoldenGate Assaytrade mark quality score metrics (Illumina Corporation, San Diego, CA, USA). We also included all putative functional SNPs (within 1 kb upstream, 5' UTR, 3' UTR or nonsynonymous) with MAF >/= 0.05 identified in Ensembl version 34 (Ensembl, European Bioinformatics Institute/Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, UK). Eight SNPs in DCN (including six functional SNPs) and six SNPs in LUM (including three functional SNPs) were identified and examined in the Mayo Clinic study based on these two methods of selection.
###end p 23
###begin p 24
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 141 143 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 144 146 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 377 378 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 168 172 <span type="species:ncbi:162683">Mayo</span>
###xml 356 360 <span type="species:ncbi:162683">Mayo</span>
The DCN and LUM SNPs were assayed at Illumina Corporation (San Diego, CA, USA) using the GoldenGate Assaytrade mark on the Illumina BeadLab [20-22] as part of a larger Mayo Clinic genetic association study. Successful genotyping was achieved for all 14 selected SNPs in the 798 cases and 843 controls. All but one of the 14 SNPs had MAF >/= 0.05 among the Mayo controls (Table 1). Concordance between 100 duplicate samples was >99.99% for all assays.
###end p 24
###begin p 25
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 133 137 <span type="species:ncbi:162683">Mayo</span>
Genetic polymorphisms in the decorin (DCN) and lumican (LUM) genes and minor allele frequencies (MAFs) among 843 Caucasian controls, Mayo Clinic 2001 to 2005
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
aLinkage disequilibrium r2 >/= 0.98 for all pairwise combinations of these SNPs.
###end p 26
###begin title 27
SEARCH replication study population
###end title 27
###begin p 28
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1027 1029 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 327 331 <span type="species:ncbi:162683">Mayo</span>
###xml 350 355 <span type="species:ncbi:9606">women</span>
Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH), an ongoing population-based study of cases with invasive breast cancer ascertained through the Eastern Cancer Registration and Information Centre in England [23], was used as a second, independent study to evaluate significant breast cancer findings in the Mayo Clinic study. All women diagnosed after 1990 in the East Anglia region (median age = 51 years, range = 25 to 69 years) were eligible, with approximately 65% of eligible breast cancer cases enrolled. Unaffected female controls (median age = 65, range = 45 to 81 years) from the same geographic region were randomly selected from the European Prospective Investigation into Cancer and Nutrition -Norfolk component of the European Prospective Investigation into Cancer and Nutrition in East Anglia, with 41% participation. Over 98% of cases and controls were white Europeans. The SEARCH study has been used extensively to evaluate associations between breast cancer risk and SNPs in various genes [23] and as part of a genome-wide association study for breast cancer [16].
###end p 28
###begin p 29
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 447 450 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 656 658 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 18 22 <span type="species:ncbi:162683">Mayo</span>
Evaluation of the Mayo Clinic findings for DCN rs3138165 and LUM rs2268578, the SNPs with the most significant associations with risk in each gene, was performed in the SEARCH study. These SNPs were selected for their strength of associations (point estimates and number of cases with two copies of the minor allele) with breast cancer risk to genotype in the SEARCH study comprising 4,470 cases and 4,560 controls with a 5' nuclease assay (Taqman(R)) using the ABI PRISM 7900 HT Sequence Detection System according to manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Primers and probes were supplied directly by Applied Biosystems [24] as Assays-by-Designtrade mark. Successful genotyping was achieved for 98.6% of DNA samples.
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 19 23 <span type="species:ncbi:162683">Mayo</span>
Genotypes from the Mayo Clinic cases and controls were used to estimate allele frequencies. Among control subjects only, the genotypes were compared with those expected under Hardy-Weinberg equilibrium using a Pearson goodness-of-fit test; no departures were found.
###end p 31
###begin p 32
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 294 299 <span type="species:ncbi:9606">women</span>
###xml 354 359 <span type="species:ncbi:9606">women</span>
Pairwise linkage disequilibrium between SNPs was estimated with r2 values [25] using Haploview [26]. Individual SNP associations for breast cancer risk were assessed using unconditional logistic regression to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). Analyses compared women with one copy and two copies of the minor allele with women with no copies using a two-degrees-of-freedom (2 df) model. We then assessed the dose-response effect of the SNP using an ordinal (log-additive) model.
###end p 32
###begin p 33
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Haplotype analyses were performed to identify whether the association with breast cancer risk could be informed further by phased combinations of alleles within each gene. Such combinations of alleles on a single chromosome can provide information about the possible presence of nearby breast cancer risk alleles that were not genotyped. Haplotype frequencies for each gene were estimated using all SNPs within the gene, and associations between individual haplotypes and breast cancer risk were evaluated compared with all other haplotypes combined. Haplotype frequencies for each gene were estimated using all SNPs within the gene, and a global haplotype score test of no association between haplotypes and breast cancer risk was evaluated at the gene level by the method proposed by Schaid and colleagues [27]. When the global haplotype score test suggested significance at the gene level, individual haplotype-specific associations for risk of breast cancer were compared with all other haplotypes combined.
###end p 33
###begin p 34
In the SEARCH study, age-adjusted single-SNP associations were conducted using unconditional logistic regression under one-copy/two-copy and ordinal genetic models as described above.
###end p 34
###begin p 35
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 34 38 <span type="species:ncbi:162683">Mayo</span>
In secondary analyses in both the Mayo Clinic and SEARCH studies, we stratified the data to evaluate the risk of breast cancer attributable to LUM rs2268578 in cases with estrogen receptor (ER)-positive and ER-negative tumors compared with control subjects because of recent reports of differential lumican protein expression by tumor ER status [10,28].
###end p 35
###begin p 36
###xml 45 47 45 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Analyses were implemented using Haplo.stats [29], the SAS software system (version 8, 1999; SAS Institute, Cary, NC, USA) and the S-Plus software system (version 7.05, 2005; Insightful Corp., Seattle, WA, USA). Given prior hypotheses that SNPs in the DCN and LUM genes are associated with breast cancer risk, corrections for multiple testing were not performed. Two-tailed P </= 0.05 was considered statistically significant.
###end p 36
###begin title 37
Results
###end title 37
###begin p 38
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 194 197 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 406 410 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 490 494 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
Eight tagSNPs in DCN representing 21 individual SNPs and six tagSNPs in LUM representing 15 individual SNPs were identified from the HapMap (Table 1 and Figure 1). Of eight tagSNPs genotyped in DCN, three were highly correlated (rs3138165, rs2070985 and rs13312816: pairwise r2 >/= 0.98). This redundancy resulted from genotyping all putative functional SNPs in addition to the tagSNPs; only data from one DCN tagSNP (rs3138165) are therefore shown in subsequent analyses. Further, another DCN tagSNP (rs3138268) had MAF = 0 among control subjects and was excluded from further analyses.
###end p 38
###begin p 39
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Linkage disequilibrium plots for polymorphisms in the <italic>DCN </italic>and <italic>LUM </italic>genes</bold>
###xml 170 174 170 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 187 190 187 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 201 205 201 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 218 221 218 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 323 324 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 343 344 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 420 421 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 421 422 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 497 501 497 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 555 556 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 556 558 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 132 136 <span type="species:ncbi:162683">Mayo</span>
Linkage disequilibrium plots for polymorphisms in the DCN and LUM genes. Linkage disequilibrium (LD) plots for polymorphisms in the Mayo Clinic sample, 2001 to 2005, for (a) the decorin (DCN) gene and (b) the lumican (LUM) gene. Shaded regions indicate strength of LD between pairwise combinations of polymorphisms (white, r2 = low LD; black, r2 = near-perfect LD). Numbers in squares indicate estimates of the pairwise r2. DCN SNP rs3138268 had minor allele frequency = 0 (absent in figure), and DCN SNPs rs3138165, rs2070985 and rs13312816 had pairwise r2 >/= 0.98: only rs3138165 was included in the statistical analyses.
###end p 39
###begin p 40
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 4 8 <span type="species:ncbi:162683">Mayo</span>
The Mayo Clinic cases and controls were adequately matched on age and region of residence, but differed in distribution by menopausal status, postmenopausal hormone use, age at menarche and smoking (Table 2). Covariates were evaluated for confounding in statistical models, and there was no appreciable difference in risk estimates of association when these covariates were excluded. The results for risk models are therefore presented adjusted for age and region of residence.
###end p 40
###begin p 41
###xml 108 112 <span type="species:ncbi:162683">Mayo</span>
Demographic, personal and lifestyle characteristics among 1,641 Caucasian breast cancer cases and controls, Mayo Clinic 2001 to 2005
###end p 41
###begin p 42
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
aPercentages may not total 100 due to missing data. bFamily history in first-degree or second-degree relative with breast cancer or ovarian cancer.
###end p 42
###begin title 43
Breast cancer risk analyses
###end title 43
###begin p 44
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 355 361 355 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 370 374 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 416 422 416 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 434 438 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 481 487 481 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 620 626 620 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 684 685 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 685 691 685 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 751 752 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 752 758 752 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 119 123 <span type="species:ncbi:162683">Mayo</span>
In the individual SNP analyses, three SNPs in DCN and three SNPs in LUM were associated with breast cancer risk in the Mayo Clinic sample: results of the one-copy/two-copy genetic model and of the ordinal model are presented in Table 3. The ORs associated with each copy of the minor allele varied slightly for DCN rs7441 (OR = 1.3, 95% CI = 1.0 to 1.7; Ptrend = 0.05), DCN rs516115 (OR = 1.2, 95% CI = 1.0 to 1.4; Ptrend = 0.03) and DCN rs3138165 (OR = 1.3, 95% CI = 1.0 to 1.8; Ptrend = 0.03). In LUM, the associations with each copy of the minor allele were similar for LUM rs2268578 (OR = 1.4, 95% CI = 1.2 to 1.8; Ptrend = 0.0003), LUM rs10859110 (OR = 1.3, 95% CI = 1.1 to 1.5; Ptrend = 0.001) and LUM rs17018765 (OR = 1.3, 95% CI = 1.0 to 1.7; Ptrend = 0.04).
###end p 44
###begin p 45
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 108 111 108 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 175 179 <span type="species:ncbi:162683">Mayo</span>
Odds ratios (OR) and 95% confidence intervals (CI)a between polymorphisms in the decorin (DCN) and lumican (LUM) genes and breast cancer risk among 1,641 Caucasian subjectsb, Mayo Clinic 2001 to 2005
###end p 45
###begin p 46
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 255 257 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
MAF, minor allele frequency. aAdjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota). b798 cases and 843 controls. cReferent (OR = 1) is homozygous common allele group. dTwo-degrees-of-freedom test, P = 0.002.
###end p 46
###begin p 47
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 29 31 29 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 167 170 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 444 446 444 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
At the gene level, only LUM (P = 0.01) showed evidence of a significant association across haplotypes for breast cancer risk (Table 4). Of nine haplotypes observed in LUM, one six-SNP haplotype (haplotype 2a) - accounting for 71% of all estimated haplotypes - was associated with decreased breast cancer risk (P = 0.01), while two separate haplotypes with 6% (haplotype 2 h) and 7% (haplotype 2i) frequency were associated with increased risk (P </= 0.03).
###end p 47
###begin p 48
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 55 58 55 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 123 127 <span type="species:ncbi:162683">Mayo</span>
Gene-levela analysis of the decorin (DCN) and lumican (LUM) genes with breast cancer risk among 1,641 Caucasian subjectsb, Mayo Clinic 2001 to 2005
###end p 48
###begin p 49
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 329 330 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 330 332 330 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 406 407 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 549 553 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
aAdjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota). b798 cases and 843 controls. cScore statistics comparing haplotype of interest with all other haplotypes combined. Negative values imply decreased risk of breast cancer, whereas positive values imply increased risk. dP value comparing haplotype of interest with all other haplotypes combined. eHaplotype-forming SNPs in DCN are rs7441 (A/G), rs516115 (A/G), rs3138165 (A/G), rs741212 (A/G), rs10492230 (A/G). fHaplotype-forming SNPs in LUM are rs1920790 (A/C), rs17714469 (G/A), rs10745553 (G/C), rs2268578 (G/A), rs10859110 (G/A), rs17018765 (A/G).
###end p 49
###begin p 50
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 525 526 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 526 531 526 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 600 601 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 601 606 601 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 705 709 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 854 855 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 855 860 855 860 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 950 951 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 951 957 951 957 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 991 995 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 117 121 <span type="species:ncbi:162683">Mayo</span>
###xml 338 343 <span type="species:ncbi:9606">women</span>
###xml 397 402 <span type="species:ncbi:9606">women</span>
###xml 474 478 <span type="species:ncbi:162683">Mayo</span>
The DCN rs3138165 and LUM rs2268578 SNPs were genotyped in the SEARCH study. The association of DCN rs3138165 in the Mayo Clinic sample was not confirmed in the SEARCH study, whereas LUM rs2268578 was positively associated with breast cancer risk but the ORs attenuated and did not reach statistical significance (Table 5). Compared with women with no copies of the minor allele in LUM rs2268578, women with two copies showed the greatest risk for breast cancer in both the Mayo Clinic sample (OR = 2.2, 95% CI = 1.1 to 4.3; P2 df = 0.002) and the SEARCH study sample (OR = 1.4, 95% CI = 1.0 to 2.1; P2 df = 0.13). When the data from the two studies were pooled in age-adjusted and study-adjusted models, LUM rs2268578 was associated with increased risk among heterozygotes (OR = 1.1, 95% CI = 1.0 to 1.2) and homozygotes (OR = 1.6, 95% CI = 1.2 to 2.3; P2 df = 0.005) (Table 5). The corresponding per-minor allele risk was 1.1 (95% CI = 1.0 to 1.2; Ptrend = 0.004). These data suggest that LUM rs2268578 or a variant in strong linkage disequilibrium with rs2268578 may be a risk factor for breast cancer.
###end p 50
###begin p 51
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 108 111 108 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
###xml 253 254 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 174 178 <span type="species:ncbi:162683">Mayo</span>
Odds ratios (OR) and 95% confidence intervals (CI)a between polymorphisms in the decorin (DCN) and lumican (LUM) genes and breast cancer risk among 1,641 Caucasian subjects (Mayo Clinic 2001 to 2005) and 9,030 Caucasian subjects (SEARCH study 1990 2005)b
###end p 51
###begin p 52
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 200 204 <span type="species:ncbi:162683">Mayo</span>
###xml 285 289 <span type="species:ncbi:162683">Mayo</span>
MAF, minor allele frequency. aMayo Clinic sample adjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota); SEARCH sample adjusted for age; pooled Mayo Clinic + SEARCH sample adjusted for age and study. b798 cases and 843 controls (Mayo Clinic sample), and 4,470 cases and 4,560 controls (SEARCH sample). cTwo-degrees-of-freedom test.
###end p 52
###begin title 53
Estrogen receptor subgroup analyses
###end title 53
###begin p 54
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 231 236 231 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 299 304 299 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 382 388 382 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 454 455 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 455 461 455 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 696 697 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 697 702 697 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 782 783 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 783 789 783 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink">trend </sub>
###xml 0 5 <span type="species:ncbi:9606">Women</span>
###xml 180 184 <span type="species:ncbi:162683">Mayo</span>
###xml 405 409 <span type="species:ncbi:162683">Mayo</span>
Women with two copies compared with no copies of the minor allele in LUM rs2268578 were at higher risk, compared with control individuals, of ER-positive breast cancer in both the Mayo Clinic study (OR = 2.5, 95% CI = 1.2 to 5.3; P2 df = 0.001) and the SEARCH study (OR = 1.6, 95% CI = 1.0 to 2.5; P2 df = 0.10) (Table 6). The per-minor allele risks were 1.5 (95% CI = 1.2 to 1.9; Ptrend = 0.0003) in the Mayo Clinic sample and 1.1 (95% CI = 0.9 to 1.2; Ptrend = 0.29) in the SEARCH sample. In pooled age-adjusted and study-adjusted analyses, LUM rs2268578 was associated with ER-positive tumors among heterozygotes (OR = 1.1, 95% CI = 0.9 to 1.2) and homozygotes (OR = 1.9, 95% CI = 1.3 to 2.8; P2 df = 0.001). The corresponding per-minor allele risk was 1.1 (95% CI = 1.0 to 1.3; Ptrend = 0.01).
###end p 54
###begin p 55
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 179 183 <span type="species:ncbi:162683">Mayo</span>
Odds ratios (OR) and 95% confidence intervals (CI)a between LUM SNP rs2268578 and breast cancer risk, stratified by tumor estrogen receptor status among 1,641 Caucasian subjects (Mayo Clinic 2001 to 2005) and 9,030 Caucasian subjects (SEARCH study 1990 to 2005)b
###end p 55
###begin p 56
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 424 425 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 164 168 <span type="species:ncbi:162683">Mayo</span>
###xml 242 246 <span type="species:ncbi:162683">Mayo</span>
###xml 404 408 <span type="species:ncbi:162683">Mayo</span>
aMayo sample adjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota); SEARCH sample adjusted for age; pooled Mayo + SEARCH sample adjusted for age and study. b798 cases and 843 controls (Mayo Clinic sample), and 4,470 cases and 4,560 controls (SEARCH sample). Numbers do not total due to missing tumor status: 1,985 (44%) in SEARCH and 206 (26%) in Mayo Clinic sample. cTwo-degrees-of-freedom test.
###end p 56
###begin p 57
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 338 342 <span type="species:ncbi:162683">Mayo</span>
The number of ER-negative cases was small in both samples and associations with breast cancer were not evident (Table 6). These data may suggest that the associations observed from the main effects models in both studies (Table 5) are due to the findings from ER-positive tumors. Almost one-half of SEARCH study tumors and one-quarter of Mayo Clinic tumors, however, could not be classified - precluding a definitive interpretation of the results, particularly for ER-negative breast cancer.
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 263 267 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 441 445 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 359 364 <span type="species:ncbi:9606">women</span>
###xml 512 516 <span type="species:ncbi:162683">Mayo</span>
###xml 665 669 <span type="species:ncbi:162683">Mayo</span>
We found a positive association between LUM rs2268578 and breast cancer risk in two large independent case-control studies, although the association in the SEARCH sample was attenuated and did not reach statistical significance. Two copies of the minor allele in LUM rs2268578 were associated with an average 60% increased risk of breast cancer compared with women with no copies, and the data suggest increased risk for ER-positive tumors. DCN rs3138165 was positively associated with breast cancer risk in the Mayo Clinic sample but the finding was not confirmed in the SEARCH sample. Haplotypes from each gene were also associated with breast cancer risk in the Mayo Clinic sample.
###end p 59
###begin p 60
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The weaker association of LUM rs2268578 with breast cancer risk in the SEARCH sample may be due to a lack of causal association of this SNP with breast cancer, or the results may be a more valid estimate of effect. It is not uncommon for replicated findings to report ORs for the variant homozygote that are weaker compared with the initial study's findings, a phenomenon known as winner's curse [30]. Furthermore, a small sample size can frequently result in insufficient power to detect minor contributions of one or more alleles [30] - as we observed with the results from the SEARCH sample.
###end p 60
###begin p 61
###xml 3 12 3 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc </italic>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 556 557 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 557 562 557 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 df </sub>
###xml 977 979 977 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1009 1011 1007 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1017 1019 1013 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 1427 1429 1423 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 351 356 <span type="species:ncbi:9606">women</span>
###xml 440 444 <span type="species:ncbi:162683">Mayo</span>
###xml 500 505 <span type="species:ncbi:9606">women</span>
###xml 1090 1094 <span type="species:ncbi:162683">Mayo</span>
###xml 1332 1336 <span type="species:ncbi:162683">Mayo</span>
In post hoc evaluation we also compared our results for LUM rs2268578 with those from the Cancer Genetic Markers of Susceptibility (CGEMS) genome-wide association study of breast cancer risk among 1,145 postmenopausal breast cancer cases and 1,142 controls of European ancestry from the Nurses' Health Study [31,32]. When restricted to postmenopausal women, the associations with breast cancer risk were weaker but remained positive in the Mayo Clinic and SEARCH samples; however, in the CGEMS data, women with one copy (OR = 1.1) or two copies (OR = 0.9, P2 df = 0.52), compared with no copies, of the minor allele were not at risk of breast cancer despite similar MAF = 0.12 among controls. The CGEMS data did not report ER-positive or ER-negative results. At MAF = 0.12, if the true OR for homozygotes is in the range 1.1 to 1.5, then a much larger study than SEARCH or CGEMS would be needed to have sufficient power to replicate the association at either the conventional (P </= 0.05) or the genome-wide (P </= 10-7) level of significance. It should be noted that, even in the combined Mayo Clinic and SEARCH samples, there were only 108 cases and 75 controls homozygous for the minor allele. Comparable information from CGEMS is not available. It remains possible that the distribution of other exposures - for example, 60% of Mayo Clinic cases did not use postmenopausal hormones versus <30% in the Nurses' Health Study [33] - may also explain the differences in genetic associations with CGEMS.
###end p 61
###begin p 62
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 303 305 303 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 955 959 955 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 430 435 <span type="species:ncbi:9606">woman</span>
The hypothesis that genetic variation in LUM is associated with breast cancer is based on a recent series of reports by Watson and colleagues of altered regulation of LUM in human breast tumors [10,11]. Using in situ hybridization and western blot techniques, LUM mRNA levels were significantly higher (P < 0.0001) in stroma associated with breast carcinoma compared with stroma associated with adjacent normal tissue in the same woman [11]. In the present study, the observed risk associated with breast cancer from the LUM intronic SNP rs2268578 or from a SNP in strong linkage disequilibrium with rs2268578 may be consistent with increased protein expression of lumican in the study by Leygue and colleagues [11], if it represents a negative host response contributing to early tumor development through increased proteolysis or altered lumican deposition that precedes disorganized collagenous stroma [11]. Elucidation of the functional impact of the LUM SNP(s) is needed in order to provide insight into the effects on risk.
###end p 62
###begin p 63
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 108 112 <span type="species:ncbi:162683">Mayo</span>
###xml 777 781 <span type="species:ncbi:162683">Mayo</span>
Associations with breast cancer risk for the DCN and LUM genes were observed with haplotype analyses in the Mayo Clinic sample. Of note, the three haplotypes in LUM that were associated with breast cancer risk had in common the G allele at position 2 (rs17714469) and a graduated change in the combination of alleles in the last three positions (rs2268578, rs10859110 and rs17018765) from GGA (haplotype 2a), associated with decreased risk, to AAA (haplotype 2h) and AAG (haplotype 2g), each associated with increased risk. It is possible that the association between breast cancer risk and these inferred haplotypes may be attributable to LUM rs2268578 or a SNP in strong linkage disequilibrium with rs2268578 because this single SNP was also associated with risk in both the Mayo Clinic and SEARCH samples. Further association testing in this chromosomal region - based on genotypes from a denser marker set - is required, however, in order to fully understand the nature of the relationship.
###end p 63
###begin p 64
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 231 240 231 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 457 459 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 499 501 499 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 593 595 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 628 630 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 896 900 894 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 1023 1027 1021 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 1138 1142 1136 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 137 141 <span type="species:ncbi:162683">Mayo</span>
###xml 567 572 <span type="species:ncbi:9606">women</span>
###xml 707 712 <span type="species:ncbi:9606">women</span>
The increased risk of breast cancer from LUM rs2268578 may be due to the positive association with ER-positive breast tumors in both the Mayo Clinic and SEARCH samples, although the analyses were underpowered and were not based on a priori hypotheses. The association between lumican expression and ER-positive breast tumors is supported by the findings from two studies [10,28]. Troup and colleagues [10] found that a greater number of ER-positive tumors (n = 99) compared with ER-negative tumors (n = 6) had lumican protein expression >/= 25th percentile among 140 women with breast cancer (P = 0.002). Mackay and colleagues [28] evaluated gene microarray expression profiles in biopsies obtained from 34 women with primary ER-positive breast cancer before and after a 2-week intervention of aromatase inhibitor treatment. Among the 2,418 genes with the greatest variability in expression, the LUM gene was the most highly upregulated by a factor, on average, of 2.9-fold following aromatase inhibitor treatment, and the DCN gene was upregulated by a factor of 2.3. Collectively, these data suggest a potential mechanistic link between LUM expression and ER-positive tumors, which requires further investigation.
###end p 64
###begin p 65
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN </italic>
###xml 745 749 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
The strengths of the present study include the incorporation of a second, independent large sample of cases and controls to confirm initial findings. Our study populations were enrolled from defined regions, were of Caucasian ancestry and were less probably influenced by population stratification [34]. This does not necessarily, however, allow generalization of the observed association with breast cancer to other ethnic/racial populations [35]. One limitation is that the classification of tumors by ER status was not centrally reviewed and a large proportion of tumors could not be classified, hampering a strong conclusion of the association of the LUM SNP by ER status. Furthermore, it remains possible that the other variants in DCN and LUM that were not selected for genotyping in SEARCH may also influence breast cancer risk.
###end p 65
###begin title 66
Conclusion
###end title 66
###begin p 67
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM </italic>
###xml 64 68 <span type="species:ncbi:162683">Mayo</span>
Although LUM rs2268578 was associated with breast cancer in the Mayo Clinic study, particularly ER-positive breast cancer, weaker and modest associations were observed in the SEARCH sample. Evaluation of this SNP in a larger study (such as the Breast Cancer Association Consortium) along with functional studies will be needed to adequately assess the importance of this SNP in breast cancer.
###end p 67
###begin title 68
Abbreviations
###end title 68
###begin p 69
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCN</italic>
###xml 121 124 121 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LUM</italic>
CGEMS: Cancer Genetic Markers of Susceptibility; DCN: decorin gene; 2 df: two degrees of freedom; ER, estrogen receptor; LUM: lumican gene; MAF: minor allele frequency; SEARCH, Studies of Epidemiology and Risk Factors in Cancer Heredity; SNP: single nucleotide polymorphism; UTR: untranslated region.
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The authors declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
###xml 41 44 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 94 97 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 185 188 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 202 206 <span type="species:ncbi:162683">Mayo</span>
###xml 305 308 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 346 350 <span type="species:ncbi:162683">Mayo</span>
LEK drafted the manuscript. LEK, FJC and CMV revised the manuscript for intellectual content. CMV conceived the study hypothesis and selected the genes. FJC, VSP, ELG, DNR, XW, JRC and CMV designed the Mayo Clinic study and acquired data. ZSF, RAV, VSP and CGS performed the statistical analyses. FJC and CMV were responsible for funding for the Mayo Clinic Study. AMD, PDPP and DFE were responsible for study design and funding for, and SA for genotyping in, the SEARCH study. All authors contributed to data interpretation, and read and approved the final manuscript.
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
The present project was supported by grants from the National Institutes of Health (NCI P50 CA116201 and NCI R01 CA122340). NCI P50 CA116201 is a Breast Specialized Program Of Research Excellence grant that provided funding for statistical analyses, interpretation of the data and writing of the manuscript. NCI R01 CA122340 also provided funding for the genotyping, statistical analyses, interpretation of the data and writing of the manuscript. SEARCH is funded through a program grant from Cancer Research UK. PDPP is a Cancer Research UK Senior Clinical Research Fellow. The decision to submit the manuscript was independent of the funding source.
###end p 75
###begin article-title 76
Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells
###end article-title 76
###begin article-title 77
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast
###end article-title 77
###begin article-title 78
Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma
###end article-title 78
###begin article-title 79
Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction
###end article-title 79
###begin article-title 80
Landscaping the cancer terrain
###end article-title 80
###begin article-title 81
Leucine-rich repeat glycoproteins of the extracellular matrix
###end article-title 81
###begin article-title 82
Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility
###end article-title 82
###begin article-title 83
Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican
###end article-title 83
###begin article-title 84
Decorin prevents metastatic spreading of breast cancer
###end article-title 84
###begin article-title 85
Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer
###end article-title 85
###begin article-title 86
###xml 52 57 <span type="species:ncbi:9606">human</span>
Lumican and decorin are differentially expressed in human breast carcinoma
###end article-title 86
###begin article-title 87
Mammographic density is related to stroma and stromal proteoglycan expression
###end article-title 87
###begin article-title 88
Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis
###end article-title 88
###begin article-title 89
Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions
###end article-title 89
###begin article-title 90
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas
###end article-title 90
###begin article-title 91
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 91
###begin article-title 92
A common coding variant in CASP8 is associated with breast cancer risk
###end article-title 92
###begin article-title 93
The International HapMap Project
###end article-title 93
###begin article-title 94
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium
###end article-title 94
###begin article-title 95
Illumina, Inc
###end article-title 95
###begin article-title 96
BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping
###end article-title 96
###begin article-title 97
BeadArray-based solutions for enabling the promise of pharmacogenomics
###end article-title 97
###begin article-title 98
Association between common variation in 120 candidate genes and breast cancer risk
###end article-title 98
###begin article-title 99
Applied Biosystems
###end article-title 99
###begin article-title 100
A comparison of linkage disequilibrium measures for fine-scale mapping
###end article-title 100
###begin article-title 101
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 101
###begin article-title 102
Score tests for association between traits and haplotypes when linkage phase is ambiguous
###end article-title 102
###begin article-title 103
Molecular response to aromatase inhibitor treatment in primary breast cancer
###end article-title 103
###begin article-title 104
###xml 0 4 <span type="species:ncbi:162683">Mayo</span>
Mayo Clinic Research
###end article-title 104
###begin article-title 105
Replicating genotype-phenotype associations
###end article-title 105
###begin article-title 106
Cancer Genetic Markers of Susceptibility
###end article-title 106
###begin article-title 107
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
###end article-title 107
###begin article-title 108
###xml 105 110 <span type="species:ncbi:9606">women</span>
Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women
###end article-title 108
###begin article-title 109
No evidence for population substructure within the EPIC-Norfolk cohort [abstract]
###end article-title 109

